I have just returned from the Drug Delivery Partnership conference in Las Vegas NV. HTI had a booth there and I had a long talk with their BD person, some of which I cannot relate here. But s a few comments I can relate are that they view the Baxter Hylenex product (launching now) as a solid opportunity but not enormous one. As stated in their presentations initial applications will be in hospice care. Further out pediatric use could also be interesting. The wild card for this company continues to be further developments with the Roche partnership or new deals with other companies on the Enhanze technology.In one of the general sessions, Roger Longman of Windover, highlighted the Roche/HTI deal and said something to the effect that he was impressed with the potential.